Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medexus Pharmaceuticals Inc MEDXF


Primary Symbol: T.MDP

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. The Company is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The Company has two divisions: Medexus Pharma Canada and Medexus Pharma USA... see more

TSX:MDP - Post Discussion

Medexus Pharmaceuticals Inc > Ebitda Sector Multiple
View:
Post by nozzpack on Aug 04, 2023 1:06pm

Ebitda Sector Multiple

Approximately 13 times for this sector..

https://firstpagesage.com/business/pharmaceutical-company-valuation-ebitda-multiples/

Trailing, MDP had $16.1 million US in Ebitda in 2022 which is about $21 million in CAD equivalent to a fair value of about $275 million CAD or about $13 per share.

MDP had Ebitda of $4,8 million US in Q4 of 2022 on $28 m in Revenur 

Projecting forward for 2023, this would be about $24 million CAD or about $310 million market cap.

That would be about $15 per share assuming no growth in 2023.

As the revenue for Q1 of 2023  is already known to be in excess of $31 million US, $15 per share may be conservative .

So, another peer based valuation shows tremendous upside here,l
Comment by nozzpack on Aug 09, 2023 6:21pm
Ebitda of $6,6 million US  in Q1 which is about $8.2 million in cad. Annualized, Thats about $33 million CAD Ebitda in this sector has a muktiple of 13 times ;( see my recent post ) which computes to a fare market cap of about $410 million cad or about $ 19 per share. This story just keeps getting better with each and every reporting quarter..
Comment by lscfa on Aug 10, 2023 7:40am
With large o/s debt, EV/ebitda multiples are more relevant.
Comment by nozzpack on Aug 10, 2023 11:35am
EV to Ebitda is 14.9.. https://www.statista.com/statistics/1030111/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-worldwide/#:~:text=Worldwide%2C%20the%20average%20value%20of,multiple%20of%20approximately%2014.9x.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities